Deep venous thrombosis associated with acquired angioedema type II in a patient heterozygous for the mutation of factor V Leiden: Effective treatment and follow-up for four years

Gábor Széplaki; Lilian Varga; Lilla Osváth; István Karádi; George Füst; Henriette Farkas

doi:10.1160/TH06-01-0062

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 95(05): 898-899
DOI: 10.1160/TH06-01-0062

Case Report

Schattauer GmbH

Deep venous thrombosis associated with acquired angioedema type II in a patient heterozygous for the mutation of factor V Leiden: Effective treatment and follow-up for four years

Gábor Széplaki

¹Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University

,

Lilian Varga

¹Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University

,

Lilla Osváth

²First Department of Dermatology, “Szent István” Hostpital; Budapest, Hungary

,

István Karádi

¹Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University

,

George Füst

¹Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University

,

Henriette Farkas

¹Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University

References
1 Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C’ 1-esterase. Am J Med 1963; 35: 37-44.
2 Caldwell J, Rudy S, Schur P. et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunpathol 1972; 01: 39-52.
3 Jackson J, Sim RB, Whelan A. et al. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722-4.
4 Alsenz J, Loos M. The acquired C1-INH deficiencies with autoantibodies (AAE type II). Behring Inst Mitt 1989; 84: 165-72.
5 Carugati A, Pappalardo E, Zingale LC. et al. C1-inhibitor deficiency and angioedema. Mol Immunol 2001; 38: 161-73.
6 Agostoni A, Aygoren-Pursun E, Binkley KE. et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114: S51-131.
7 Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-15.
8 Wautier JL, Ollier-Hartmann MP, Kadeva H. et al. First component of complement and thrombosis. Thromb Haemost 1981; 45: 247-51.
9 Farkas H, Varga L. The Hungarian HAE experience. Transfus Apher Sci 2003; 29: 229-33.
10 Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93: 870-6.
11 Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24: 599-606.
12 Ravindran S, Grys TE, Welch RA. et al. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost 2004; 92: 1277-83.
13 Cugno M, Cicardi M, Coppola R. et al. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996; 33: 361-4.